{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T01:04:18Z","timestamp":1795223058881,"version":"4.10.3"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41571-026-01160-z","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:30:57Z","timestamp":1781080257000},"page":"619-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Trial design and end points in hepatocellular carcinoma: an EASL\u2013AASLD\u2013ILCA consensus statement"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-2667","authenticated-orcid":false,"given":"Josep M.","family":"Llovet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-7676","authenticated-orcid":false,"given":"Ezequiel","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-8574","authenticated-orcid":false,"given":"Lewis","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Casanovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-336X","authenticated-orcid":false,"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-0748","authenticated-orcid":false,"given":"Mark","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-2126","authenticated-orcid":false,"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-3971","authenticated-orcid":false,"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"1160_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal, A. G., Kanwal, F. & Llovet, J. M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat. Rev. Clin. Oncol. 20, 864\u2013884 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1160_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1160_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101571","volume":"7","author":"E Mauro","year":"2025","unstructured":"Mauro, E. et al. Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep. 7, 101571 (2025).","journal-title":"JHEP Rep."},{"key":"1160_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hep.31327","volume":"73","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 73, 158\u2013191 (2021).","journal-title":"Hepatology"},{"key":"1160_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","volume":"36","author":"NI Cherny","year":"2025","unstructured":"Cherny, N. I. et al. ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). Ann. Oncol. 36, 866\u2013908 (2025).","journal-title":"Ann. Oncol."},{"key":"1160_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101553","volume":"7","author":"E Mauro","year":"2025","unstructured":"Mauro, E. & Serra-Burriel, M. ESMO-MCBS v2.0: advances, challenges, and perspectives in the assessment of clinical benefit in oncology. JHEP Rep. 7, 101553 (2025).","journal-title":"JHEP Rep."},{"key":"1160_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2022.100364","volume":"34","author":"A Walia","year":"2022","unstructured":"Walia, A., Haslam, A. & Prasad, V. FDA validation of surrogate endpoints in oncology: 2005\u20132022. J. Cancer Policy 34, 100364 (2022).","journal-title":"J. Cancer Policy"},{"key":"1160_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1470-2045(25)00150-0","volume":"26","author":"M Pe","year":"2025","unstructured":"Pe, M. et al. Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop. Lancet Oncol. 26, 687\u2013690 (2025).","journal-title":"Lancet Oncol."},{"key":"1160_CR9","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"1160_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","volume":"36","author":"A Vogel","year":"2025","unstructured":"Vogel, A. et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 36,\u00a0491\u2013506\u00a0(2025).","journal-title":"Ann. Oncol."},{"key":"1160_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82, 315\u2013374 (2025).","journal-title":"J. Hepatol."},{"key":"1160_CR12","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/OP.24.00189","volume":"20","author":"MG Rose","year":"2024","unstructured":"Rose, M. G. et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update clinical insights. JCO Oncol. Pract. 20, 1035\u20131039 (2024).","journal-title":"JCO Oncol. Pract."},{"key":"1160_CR13","first-page":"10","volume":"12","author":"C-C Hsu","year":"2007","unstructured":"Hsu, C.-C. & Sandford, B. A. The delphi technique: making sense of consensus. PARE 12, 10 (2007).","journal-title":"PARE"},{"key":"1160_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41571-024-00945-4","volume":"21","author":"S Banerjee","year":"2024","unstructured":"Banerjee, S. et al. Two decades of advances in clinical oncology \u2014 lessons learned and future directions. Nat. Rev. Clin. Oncol. 21, 771\u2013780 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1160_CR15","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1200\/JCO.21.02125","volume":"40","author":"M Bittlinger","year":"2022","unstructured":"Bittlinger, M., Bicer, S., Peppercorn, J. & Kimmelman, J. Ethical considerations for phase I trials in oncology. J. Clin. Oncol. 40, 3474\u20133488 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/jnci\/djaf013","volume":"117","author":"C Ouimet","year":"2025","unstructured":"Ouimet, C., Fodor, B., Del Paggio, J. C. & Kimmelman, J. Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved. J. Natl Cancer Inst. 117, 1056\u20131063 (2025).","journal-title":"J. Natl Cancer Inst."},{"key":"1160_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-023-00731-8","volume":"20","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. Exploring a new pathway for biomarker-based approval of immunotherapies. Nat. Rev. Clin. Oncol. 20, 279\u2013280 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1160_CR18","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-08-2031","volume":"15","author":"L Rubinstein","year":"2009","unstructured":"Rubinstein, L., Crowley, J., Ivy, P., Leblanc, M. & Sargent, D. Randomized phase II designs. Clin. Cancer Res. 15, 1883\u20131890 (2009).","journal-title":"Clin. Cancer Res."},{"key":"1160_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijrobp.2021.07.1700","volume":"112","author":"PA Torres-Saavedra","year":"2022","unstructured":"Torres-Saavedra, P. A. & Winter, K. A. An overview of phase 2 clinical trial designs. Int. J. Radiat. Oncol. Biol. Phys. 112, 22\u201329 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1160_CR20","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1200\/JCO.23.00413","volume":"41","author":"B Freidlin","year":"2023","unstructured":"Freidlin, B., Korde, L. A. & Korn, E. L. Timing and reporting of secondary overall survival end points for phase III trials in advanced\/metastatic disease. J. Clin. Oncol. 41, 4616\u20134620 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR21","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-12-2934","volume":"19","author":"RL Korn","year":"2013","unstructured":"Korn, R. L. & Crowley, J. J. Overview: Progression-free survival as an endpoint in clinical trials with solid tumors. Clin. Cancer Res. 19, 2607\u20132612 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1160_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/jnci\/djac210","volume":"115","author":"F Liang","year":"2023","unstructured":"Liang, F., Peng, L., Wu, Z., Giamas, G. & Stebbing, J. Design and reporting of phase III oncology trials with prospective biomarker validation. J. Natl Cancer Inst. 115, 174\u2013180 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"1160_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/2229-3485.71852","volume":"1","author":"DV Suvarna","year":"2010","unstructured":"Suvarna, D. V. Phase IV of drug development. Perspect. Clin. Res. 1, 57\u201360 (2010).","journal-title":"Perspect. Clin. Res."},{"key":"1160_CR24","unstructured":"US Food and Drug Administration. Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics (FDA, 2023)."},{"key":"1160_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ejca.2012.09.035","volume":"49","author":"CA Bellera","year":"2013","unstructured":"Bellera, C. A. et al. Protocol of the definition for the assessment of time-to-event endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints\u2019 definitions in cancer clinical trials. Eur. J. Cancer 49, 769\u2013781 (2013).","journal-title":"Eur. J. Cancer"},{"key":"1160_CR26","doi-asserted-by":"publisher","first-page":"102824","DOI":"10.1016\/j.eclinm.2024.102824","volume":"76","author":"A Mittal","year":"2024","unstructured":"Mittal, A., Kim, M. S., Dunn, S., Wright, K. & Gyawali, B. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward. EClinicalMedicine 76, 102824 (2024).","journal-title":"EClinicalMedicine"},{"key":"1160_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1160_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet, J. M. & Lencioni, R. mRECIST for HCC: performance and novel refinements. J. Hepatol. 72, 288\u2013306 (2020).","journal-title":"J. Hepatol."},{"key":"1160_CR29","unstructured":"National Cancer Institute. Resources for Researchers: Common Terminology Criteria for Adverse Events (CTCAE) https:\/\/www.cancer.gov\/research\/resources\/resource\/210 (NCI, 2026)."},{"key":"1160_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101473","volume":"7","author":"M Riveiro-Barciela","year":"2025","unstructured":"Riveiro-Barciela, M. & De Martin, E. Navigating liver toxicity in the age of novel oncological agents. JHEP Rep. 7, 101473 (2025).","journal-title":"JHEP Rep."},{"key":"1160_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/hep.32313","volume":"76","author":"M Serper","year":"2022","unstructured":"Serper, M. et al. Patient-reported outcomes in HCC: a scoping review by the practice metrics committee of the American Association for the Study of Liver Diseases. Hepatology 76, 251\u2013274 (2022).","journal-title":"Hepatology"},{"key":"1160_CR32","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","volume":"7","author":"JC Del Paggio","year":"2021","unstructured":"Del Paggio, J. C. et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 7, 728\u2013734 (2021).","journal-title":"JAMA Oncol."},{"key":"1160_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad, V., Kim, C., Burotto, M. & Vandross, A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern. Med. 175, 1389\u20131398 (2015).","journal-title":"JAMA Intern. Med."},{"key":"1160_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1200\/JCO.21.01548","volume":"40","author":"KJ Norsworthy","year":"2022","unstructured":"Norsworthy, K. J. et al. Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses. J. Clin. Oncol. 40, 847\u2013854 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0416","volume":"1","author":"B Gyawali","year":"2018","unstructured":"Gyawali, B., Hey, S. P. & Kesselheim, A. S. A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and differences in effect sizes. JAMA Netw. Open 1, e180416 (2018).","journal-title":"JAMA Netw. Open"},{"key":"1160_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","volume":"77","author":"AG Singal","year":"2022","unstructured":"Singal, A. G. et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J. Hepatol. 77, 128\u2013139 (2022).","journal-title":"J. Hepatol."},{"key":"1160_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jhep.2023.02.022","volume":"79","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance. J. Hepatol. 79, 226\u2013239 (2023).","journal-title":"J. Hepatol."},{"key":"1160_CR38","doi-asserted-by":"publisher","first-page":"102755","DOI":"10.1016\/j.eclinm.2024.102755","volume":"75","author":"SYZ Kao","year":"2024","unstructured":"Kao, S. Y. Z. et al. Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis. EClinicalMedicine 75, 102755 (2024).","journal-title":"EClinicalMedicine"},{"key":"1160_CR39","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","volume":"154","author":"K Tzartzeva","year":"2018","unstructured":"Tzartzeva, K. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154, 1706\u20131718.e1 (2018).","journal-title":"Gastroenterology"},{"key":"1160_CR40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.31309","volume":"73","author":"E Wolf","year":"2021","unstructured":"Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D. & Singal, A. G. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology 73, 713\u2013725 (2021).","journal-title":"Hepatology"},{"key":"1160_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2022.08.036","volume":"78","author":"ND Parikh","year":"2023","unstructured":"Parikh, N. D., Tayob, N. & Singal, A. G. Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era? J. Hepatol. 78, 207\u2013216 (2023).","journal-title":"J. Hepatol."},{"key":"1160_CR42","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","volume":"93","author":"MS Pepe","year":"2001","unstructured":"Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054\u20131061 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"1160_CR43","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1053\/j.gastro.2021.01.233","volume":"160","author":"AG Singal","year":"2021","unstructured":"Singal, A. G. et al. International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology 160, 2572\u20132584 (2021).","journal-title":"Gastroenterology"},{"key":"1160_CR44","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/HEP.0000000000001203","volume":"82","author":"AG Singal","year":"2024","unstructured":"Singal, A. G. et al. Value of HCC surveillance in a landscape of emerging surveillance options: perspectives of a multi-stakeholder modified Delphi panel. Hepatology\u00a082, 794\u2013809\u00a0(2024).","journal-title":"Hepatology"},{"key":"1160_CR45","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.14309\/ajg.0000000000003494","volume":"120","author":"AG Singal","year":"2025","unstructured":"Singal, A. G. et al. Patient-perceived risk of HCC and net benefit of surveillance: a multi-center survey study. Am. J. Gastroenterol. 120, 1800\u20131808 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1160_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16142","volume":"45","author":"E Mauro","year":"2025","unstructured":"Mauro, E. et al. New scenarios in liver transplantation for hepatocellular carcinoma. Liver Int. 45, e16142 (2025).","journal-title":"Liver Int."},{"key":"1160_CR47","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet, J. M. et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 21, 294\u2013311 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1160_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","volume":"38","author":"H Imamura","year":"2003","unstructured":"Imamura, H. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38, 200\u2013207 (2003).","journal-title":"J. Hepatol."},{"key":"1160_CR49","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/hep.21415","volume":"44","author":"V Mazzaferro","year":"2006","unstructured":"Mazzaferro, V. et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44, 1543\u20131554 (2006).","journal-title":"Hepatology"},{"key":"1160_CR50","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2024.01.018","volume":"80","author":"G Cabibbo","year":"2024","unstructured":"Cabibbo, G. et al. Navigating the landscape of liver cancer management: study designs in clinical trials and clinical practice. J. Hepatol. 80, 957\u2013966 (2024).","journal-title":"J. Hepatol."},{"key":"1160_CR51","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","volume":"81","author":"C Fuster-Anglada","year":"2024","unstructured":"Fuster-Anglada, C. et al. Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J. Hepatol. 81, 995\u20131004 (2024).","journal-title":"J. Hepatol."},{"key":"1160_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron, T. U. et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 219\u2013229 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1160_CR53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb, A. O. et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 208\u2013218 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1160_CR54","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D\u2019Alessio","year":"2024","unstructured":"D\u2019Alessio, A. et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 25, 1465\u20131475 (2024).","journal-title":"Lancet Oncol."},{"key":"1160_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08033-x","volume":"21","author":"DJ Pinato","year":"2021","unstructured":"Pinato, D. J. et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer 21, 301 (2021).","journal-title":"BMC Cancer"},{"key":"1160_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004656","volume":"10","author":"Y Xia","year":"2022","unstructured":"Xia, Y. et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J. Immunother. Cancer 10, e004656 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1160_CR57","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho, W. J. et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat. Cancer 2, 891\u2013903 (2021).","journal-title":"Nat. Cancer"},{"key":"1160_CR58","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","volume":"406","author":"Z Wang","year":"2025","unstructured":"Wang, Z. et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial. Lancet 406, 2089\u20132099 (2025).","journal-title":"Lancet"},{"key":"1160_CR59","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix, J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16, 1344\u20131354 (2015).","journal-title":"Lancet Oncol."},{"key":"1160_CR60","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/HEP.0000000000001233","volume":"82","author":"T Ma","year":"2025","unstructured":"Ma, T. et al. Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: a randomized, open-label, phase 3 trial. Hepatology 82, 1112\u20131121 (2025).","journal-title":"Hepatology"},{"key":"1160_CR61","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402, 1835\u20131847 (2023).","journal-title":"Lancet"},{"key":"1160_CR62","doi-asserted-by":"publisher","first-page":"S1230","DOI":"10.1016\/j.annonc.2024.08.2279","volume":"35","author":"A Yopp","year":"2024","unstructured":"Yopp, A. et al. Updated efficacy and safety data from IMbrave050: phase 3 study of adjuvant atezolizumab\u2009(atezo) +\u2009bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) [abstract LBA39]. Ann. Oncol. 35, S1230 (2024).","journal-title":"Ann. Oncol."},{"key":"1160_CR63","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","volume":"84","author":"A Yopp","year":"2026","unstructured":"Yopp, A. et al. Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J. Hepatol. 84,\u00a01102\u20131111 (2026).","journal-title":"J. Hepatol."},{"key":"1160_CR64","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jhep.2025.08.042","volume":"84","author":"E Mauro","year":"2025","unstructured":"Mauro, E. et al. Strategies to address non-proportional hazards between survival curves \u2014 lessons from phase III trials in hepatocellular carcinoma. J. Hepatol. 84, 567\u2013577 (2025).","journal-title":"J. Hepatol."},{"key":"1160_CR65","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M. & Roayaie, S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg. 261, 947\u2013955 (2015).","journal-title":"Ann. Surg."},{"key":"1160_CR66","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/lt.20202","volume":"10","author":"M Sala","year":"2004","unstructured":"Sala, M. et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transplant. 10, 1294\u20131300 (2004).","journal-title":"Liver Transplant."},{"key":"1160_CR67","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2018.08.027","volume":"69","author":"AWH Chan","year":"2018","unstructured":"Chan, A. W. H. et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J. Hepatol. 69, 1284\u20131293 (2018).","journal-title":"J. Hepatol."},{"key":"1160_CR68","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1160_CR69","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N. Engl. J. Med. 391, 1981\u20131991 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1160_CR70","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep.25832","volume":"57","author":"S Roayaie","year":"2013","unstructured":"Roayaie, S. et al. Resection of hepatocellular cancer \u22642\u2009cm: results from two Western centers. Hepatology 57, 1426\u20131435 (2013).","journal-title":"Hepatology"},{"key":"1160_CR71","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejso.2021.09.012","volume":"48","author":"BR Beumer","year":"2022","unstructured":"Beumer, B. R. et al. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur. J. Surgical Oncol. 48, 492\u2013499 (2022).","journal-title":"Eur. J. Surgical Oncol."},{"key":"1160_CR72","unstructured":"US Food and Drug Administration. Approaches to Assessment of Overall Survival in Oncology Clinical Trials https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/approaches-assessment-overall-survival-oncology-clinical-trials (FDA, 2025)."},{"key":"1160_CR73","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","volume":"82","author":"TH Taddei","year":"2025","unstructured":"Taddei, T. H., Brown, D. B., Yarchoan, M., Mendiratta-Lala, M. & Llovet, J. M. Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 82, 272\u2013274 (2025).","journal-title":"Hepatology"},{"key":"1160_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000430","volume":"8","author":"AG Singal","year":"2024","unstructured":"Singal, A. G. et al. Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future. Hepatol. Commun. 8, e0430 (2024).","journal-title":"Hepatol. Commun."},{"key":"1160_CR75","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 293\u2013313 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1160_CR76","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164\u20131171 (2002).","journal-title":"Hepatology"},{"key":"1160_CR77","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734\u20131739 (2002).","journal-title":"Lancet"},{"key":"1160_CR78","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429\u2013442 (2003).","journal-title":"Hepatology"},{"key":"1160_CR79","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 405, 216\u2013232\u00a0(2025).","journal-title":"Lancet"},{"key":"1160_CR80","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo, M. et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet\u00a0405, 203\u2013215\u00a0(2025).","journal-title":"Lancet"},{"key":"1160_CR81","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","volume":"36","author":"J Dong","year":"2025","unstructured":"Dong, J. et al. TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab\u2009+\u2009bevacizumab (Atezo\u2009+\u2009Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) [abstract LBA2]. Ann. Oncol. 36, S62 (2025).","journal-title":"Ann. Oncol."},{"key":"1160_CR82","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt, E. et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology 303, 699\u2013710 (2022).","journal-title":"Radiology"},{"key":"1160_CR83","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2468-1253(24)00267-X","volume":"10","author":"SO Dudzinski","year":"2025","unstructured":"Dudzinski, S. O. et al. Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma. Lancet Gastroenterol. Hepatol. 10, 387\u2013398 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1160_CR84","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","volume":"11","author":"LA Dawson","year":"2025","unstructured":"Dawson, L. A. et al. Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 11, 136\u2013144 (2025).","journal-title":"JAMA Oncol."},{"key":"1160_CR85","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1160_CR86","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","volume":"70","author":"JM Llovet","year":"2019","unstructured":"Llovet, J. M., Montal, R. & Villanueva, A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J. Hepatol. 70, 1262\u20131277 (2019).","journal-title":"J. Hepatol."},{"key":"1160_CR87","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","volume":"21","author":"KN Vokinger","year":"2020","unstructured":"Vokinger, K. N. et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost\u2013benefit analysis. Lancet Oncol. 21, 664\u2013670 (2020).","journal-title":"Lancet Oncol."},{"key":"1160_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133488","volume":"10","author":"B Vincenzi","year":"2015","unstructured":"Vincenzi, B. et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS ONE 10, e0133488 (2015).","journal-title":"PLoS ONE"},{"key":"1160_CR89","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/hepr.13746","volume":"52","author":"M Kudo","year":"2022","unstructured":"Kudo, M. et al. Response Evaluation Criteria in Cancer of the Liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version). Hepatol. Res. 52, 329\u2013336 (2022).","journal-title":"Hepatol. Res."},{"key":"1160_CR90","first-page":"LBA522","volume":"43","author":"H Zhu","year":"2025","unstructured":"Zhu, H. et al. Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: a multicenter, open-label, randomized, phase 2 study (CAP-ACE) [abstract]. J. Clin. Oncol. 43, LBA522 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR91","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"1160_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10, 35\u201343 (2009).","journal-title":"Lancet Oncol."},{"key":"1160_CR93","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","volume":"70","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J. Hepatol. 70, 893\u2013903 (2019).","journal-title":"J. Hepatol."},{"key":"1160_CR94","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1159\/000508809","volume":"9","author":"K Koroki","year":"2020","unstructured":"Koroki, K. et al. Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization prior to designing clinical trials. Liver Cancer 9, 596\u2013612 (2020).","journal-title":"Liver Cancer"},{"key":"1160_CR95","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/bjc.2016.423","volume":"116","author":"I Waked","year":"2017","unstructured":"Waked, I. et al. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br. J. Cancer 116, 448\u2013454 (2017).","journal-title":"Br. J. Cancer"},{"key":"1160_CR96","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow, P. K. H. et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J. Clin. Oncol. 36, 1913\u20131921 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR97","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693\u2013700 (1996).","journal-title":"N. Engl. J. Med."},{"key":"1160_CR98","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","volume":"21","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro, V. et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial. Lancet Oncol. 21, 947\u2013956 (2020).","journal-title":"Lancet Oncol."},{"key":"1160_CR99","first-page":"779","volume":"157","author":"P Tabrizian","year":"2022","unstructured":"Tabrizian, P. et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 157, 779\u2013788 (2022).","journal-title":"JAMA Surg."},{"key":"1160_CR100","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","volume":"81","author":"European Association for the Study of the Liver","year":"2024","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines on liver transplantation. J. Hepatol. 81, 1040\u20131086 (2024).","journal-title":"J. Hepatol."},{"key":"1160_CR101","first-page":"743","volume":"14","author":"A Vitale","year":"2025","unstructured":"Vitale, A. et al. The concept of \u2018converse therapeutic hierarchy\u2019 for patients with hepatocellular carcinoma. Liver Cancer 14,\u00a0743\u2013757\u00a0(2025).","journal-title":"Liver Cancer"},{"key":"1160_CR102","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2024.05.037","volume":"81","author":"M Li","year":"2024","unstructured":"Li, M., Bhoori, S., Mehta, N. & Mazzaferro, V. Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation. J. Hepatol. 81, 743\u2013755 (2024).","journal-title":"J. Hepatol."},{"key":"1160_CR103","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.suc.2023.07.009","volume":"104","author":"P Tabrizian","year":"2024","unstructured":"Tabrizian, P., Yu, A., Debnath, N., Myers, B. & Marron, T. Immunotherapy and liver transplantation: the future or the failure? Surg. Clin. North. Am. 104, 163\u2013182 (2024).","journal-title":"Surg. Clin. North. Am."},{"key":"1160_CR104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","volume":"82","author":"MS Rezaee-Zavareh","year":"2024","unstructured":"Rezaee-Zavareh, M. S. et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis. J. Hepatol. 82, 107\u2013119\u00a0(2024).","journal-title":"J. Hepatol."},{"key":"1160_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173059","volume":"16","author":"E Mauro","year":"2024","unstructured":"Mauro, E. et al. Challenges in liver transplantation for hepatocellular carcinoma: a review of current controversies. Cancers. 16, 3059 (2024).","journal-title":"Cancers."},{"key":"1160_CR106","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","volume":"154","author":"V Mazzaferro","year":"2018","unstructured":"Mazzaferro, V. et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 154, 128\u2013139 (2018).","journal-title":"Gastroenterology"},{"key":"1160_CR107","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","volume":"143","author":"C Duvoux","year":"2012","unstructured":"Duvoux, C. et al. Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of milan criteria. Gastroenterology 143, 986\u2013994.e3 (2012).","journal-title":"Gastroenterology"},{"key":"1160_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100557","volume":"4","author":"H Toyoda","year":"2022","unstructured":"Toyoda, H. & Johnson, P. J. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. 4, 100557 (2022).","journal-title":"JHEP Rep."},{"key":"1160_CR109","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/hep.30879","volume":"71","author":"N Mehta","year":"2020","unstructured":"Mehta, N., Dodge, J. L., Grab, J. D. & Yao, F. Y. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time. Hepatology 71, 943\u2013954 (2020).","journal-title":"Hepatology"},{"key":"1160_CR110","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.cgh.2021.07.048","volume":"20","author":"AJ Kwong","year":"2022","unstructured":"Kwong, A. J. et al. National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States. Clin. Gastroenterol. Hepatol. 20, 1142\u20131150.e4 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1160_CR111","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jvir.2024.10.034","volume":"36","author":"R Salem","year":"2025","unstructured":"Salem, R., Kwong, A. J., Kim, N., Sze, D. Y. & Mehta, N. Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the United States. J. Vasc. Interv. Radiol. 36, 362\u2013363 (2025).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1160_CR112","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jvir.2025.05.009","volume":"36","author":"A Sher","year":"2025","unstructured":"Sher, A. et al. Histopathologic response and oncologic outcomes after segmental and subsegmental transarterial chemoembolization and radioembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol. 36, 1285\u20131295.e2 (2025).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1160_CR113","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/j.1600-6143.2007.02138.x","volume":"8","author":"ML Volk","year":"2008","unstructured":"Volk, M. L., Vijan, S. & Marrero, J. A. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am. J. Transpl. 8, 839\u2013846 (2008).","journal-title":"Am. J. Transpl."},{"key":"1160_CR114","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","volume":"82","author":"P Tabrizian","year":"2024","unstructured":"Tabrizian, P. et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study. J. Hepatol. 82,\u00a0512\u2013522\u00a0(2024).","journal-title":"J. Hepatol."},{"key":"1160_CR115","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1160_CR116","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"1160_CR117","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau, T. et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 405,\u00a01851\u20131864\u00a0(2025).","journal-title":"Lancet"},{"key":"1160_CR118","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1160_CR119","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"1160_CR120","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S. & Llovet, J. M. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 10, 395\u2013404 (2024).","journal-title":"JAMA Oncol."},{"key":"1160_CR121","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 9, 1651\u20131659 (2023).","journal-title":"JAMA Oncol."},{"key":"1160_CR122","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","volume":"81","author":"SL Chan","year":"2024","unstructured":"Chan, S. L. et al. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J. Hepatol. 81, 258\u2013264 (2024).","journal-title":"J. Hepatol."},{"key":"1160_CR123","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jhep.2025.08.020","volume":"84","author":"H-D Kim","year":"2025","unstructured":"Kim, H.-D. et al. Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab. J. Hepatol. 84, 308\u2013315 (2025).","journal-title":"J. Hepatol."},{"key":"1160_CR124","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000543666","volume":"14","author":"J Cheon","year":"2025","unstructured":"Cheon, J. et al. Multicenter phase 2 trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on atezolizumab plus bevacizumab. Liver Cancer 14, 446\u2013455 (2025).","journal-title":"Liver Cancer"},{"key":"1160_CR125","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1007\/s00432-022-04206-8","volume":"149","author":"D Roessler","year":"2023","unstructured":"Roessler, D. et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. J. Cancer Res. Clin. Oncol. 149, 3065\u20133073 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1160_CR126","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282\u2013296 (2019).","journal-title":"Lancet Oncol."},{"key":"1160_CR127","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1200\/JCO.22.00620","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial. J. Clin. Oncol. 41, 1434\u20131443 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR128","first-page":"655","volume":"13","author":"RS Finn","year":"2024","unstructured":"Finn, R. S. et al. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150. Liver Cancer\u00a013,\u00a0655\u2013668\u00a0(2024).","journal-title":"Liver Cancer"},{"key":"1160_CR129","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","volume":"12","author":"S Apisarnthanarax","year":"2022","unstructured":"Apisarnthanarax, S. et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract. Radiat. Oncol. 12, 28\u201351 (2022).","journal-title":"Pract. Radiat. Oncol."},{"key":"1160_CR130","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/gutjnl-2025-334928","volume":"74","author":"M Pinter","year":"2025","unstructured":"Pinter, M., Fulgenzi, C. A. M., Pinato, D. J. & Scheiner, B. Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction. Gut 74, 1178\u20131188 (2025).","journal-title":"Gut"},{"key":"1160_CR131","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/HEP.0000000000000030","volume":"77","author":"I El Hajra","year":"2022","unstructured":"El Hajra, I., Sanduzzi-Zamparelli, M. & Sapena, V. Outcome of patients with hepatocellular carcinoma and liver dysfunction under immunotherapy: a systematic review and meta-analysis. Hepatology 77, 1139\u20131149 (2022).","journal-title":"Hepatology"},{"key":"1160_CR132","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","volume":"10","author":"CAM Fulgenzi","year":"2024","unstructured":"Fulgenzi, C. A. M. et al. Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction. JAMA Oncol. 10, 1253\u20131258 (2024).","journal-title":"JAMA Oncol."},{"key":"1160_CR133","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/hep.32468","volume":"76","author":"A D\u2019Alessio","year":"2022","unstructured":"D\u2019Alessio, A. et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology 76, 1000\u20131012 (2022).","journal-title":"Hepatology"},{"key":"1160_CR134","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00228-025-03820-y","volume":"81","author":"K Jiang","year":"2025","unstructured":"Jiang, K. et al. Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Eur. J. Clin. Pharmacol. 81, 727\u2013737 (2025).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"1160_CR135","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.jhep.2025.07.020","volume":"83","author":"G Cabibbo","year":"2025","unstructured":"Cabibbo, G. et al. Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma. J. Hepatol. 83, 1443\u20131451 (2025).","journal-title":"J. Hepatol."},{"key":"1160_CR136","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"1160_CR137","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456 (2021).","journal-title":"Nature"},{"key":"1160_CR138","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1053\/j.gastro.2023.04.014","volume":"165","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. & Heikenwalder, M. Atezolizumab plus bevacizumab in advanced HCC: efficacy in NASH-specific etiology. Gastroenterology 165, 1308\u20131310 (2023).","journal-title":"Gastroenterology"},{"key":"1160_CR139","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","volume":"79","author":"T Meyer","year":"2023","unstructured":"Meyer, T., Galani, S., Lopes, A. & Vogel, A. Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease. J. Hepatol. 79, e73\u2013e76 (2023).","journal-title":"J. Hepatol."},{"key":"1160_CR140","doi-asserted-by":"publisher","first-page":"101630","DOI":"10.1016\/j.jhepr.2025.101630","volume":"8","author":"A Vogel","year":"2025","unstructured":"Vogel, A., Saborowski, A., Rimassa, L. & El-Khoueiry, A. Navigating second-line therapy after immunotherapy in advanced HCC. JHEP Rep. 8,\u00a0101630 (2025).","journal-title":"JHEP Rep."},{"key":"1160_CR141","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","volume":"34","author":"LE Schnipper","year":"2016","unstructured":"Schnipper, L. E. et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J. Clin. Oncol. 34, 2925\u20132933 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR142","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","volume":"20","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat. Rev. Gastroenterol. Hepatol. 20, 487\u2013503 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1160_CR143","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","volume":"19","author":"L Rimassa","year":"2018","unstructured":"Rimassa, L. et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 19, 682\u2013693 (2018).","journal-title":"Lancet Oncol."},{"key":"1160_CR144","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"CL Hsu","year":"2021","unstructured":"Hsu, C. L. et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer 10, 346\u2013359 (2021).","journal-title":"Liver Cancer"},{"key":"1160_CR145","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-22-1213","volume":"28","author":"S Cappuyns","year":"2022","unstructured":"Cappuyns, S. & Llovet, J. M. Combination therapies for advanced hepatocellular carcinoma: biomarkers and unmet needs. Clin. Cancer Res. 28, 3405\u20133407 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1160_CR146","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","volume":"156","author":"M Teufel","year":"2019","unstructured":"Teufel, M. et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology 156, 1731\u20131741 (2019).","journal-title":"Gastroenterology"},{"key":"1160_CR147","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","volume":"82","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns, S. et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab\u2009+\u2009bevacizumab in advanced hepatocellular carcinoma. J. Hepatol. 82,\u00a01036\u20131049 (2024).","journal-title":"J. Hepatol."},{"key":"1160_CR148","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611 (2022).","journal-title":"Nat. Med."},{"key":"1160_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117298","volume":"87","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors. Bioorg. Med. Chem. 87, 117298 (2023).","journal-title":"Bioorg. Med. Chem."},{"key":"1160_CR150","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","volume":"28","author":"A Couzinet","year":"2024","unstructured":"Couzinet, A., Suzuki, T. & Nakatsura, T. Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy. Expert. Opin. Ther. Targets 28, 895\u2013909 (2024).","journal-title":"Expert. Opin. Ther. Targets"},{"key":"1160_CR151","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.cell.2026.03.001","volume":"189","author":"JM Llovet","year":"2026","unstructured":"Llovet, J. M. et al. Hallmarks of liver cancer: therapeutic implications. Cell 189, 2490\u20132514 (2026).","journal-title":"Cell"},{"key":"1160_CR152","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.14309\/ajg.0000000000003551","volume":"120","author":"AP Desai","year":"2025","unstructured":"Desai, A. P., Scherer, A. N. & Serper, M. The role of patient-reported outcomes in cirrhosis. Am. J. Gastroenterol. 120, 1708\u20131719 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1160_CR153","unstructured":"European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man \u2014 the use of patient-reported outcome (PRO) measures in oncology studies \u2014 Scientific guideline https:\/\/www.ema.europa.eu\/en\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man-use-patient-reported-outcome-pro-measures-oncology-studies-scientific-guideline (EMA, 2016)."},{"key":"1160_CR154","doi-asserted-by":"crossref","unstructured":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research; US Department of Health and Human Services FDA Center for Biologics Evaluation and Research; US Department of Health and Human Services FDA Center for Devices and Radiological Health Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual. Life Outcomes 4, 79 (2006).","DOI":"10.1186\/1477-7525-4-79"},{"key":"1160_CR155","unstructured":"US Food and Drug Administration. Core Patient-Reported Outcomes in Cancer Clinical Trials https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials (FDA, 2024)."},{"key":"1160_CR156","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365\u2013376 (1993).","journal-title":"J. Natl Cancer Inst."},{"key":"1160_CR157","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella, D. F. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11, 570\u2013579 (1993).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR158","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.ejca.2004.06.033","volume":"40","author":"JM Blazeby","year":"2004","unstructured":"Blazeby, J. M. et al. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur. J. Cancer 40, 2439\u20132444 (2004).","journal-title":"Eur. J. Cancer"},{"key":"1160_CR159","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","volume":"20","author":"N Heffernan","year":"2002","unstructured":"Heffernan, N. et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the Functional Assessment of Cancer Therapy\u2013Hepatobiliary questionnaire. J. Clin. Oncol. 20, 2229\u20132239 (2002).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR160","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2025.2470","volume":"11","author":"C Celsa","year":"2025","unstructured":"Celsa, C. et al. Integrating quality of life and survival in systemic therapy for advanced hepatocellular carcinoma: a network meta-analysis. JAMA Oncol. 11,\u00a01160\u20131168 (2025).","journal-title":"JAMA Oncol."},{"key":"1160_CR161","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.annonc.2022.12.004","volume":"34","author":"SF Oosting","year":"2023","unstructured":"Oosting, S. F. et al. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology\u2013Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. Ann. Oncol. 34, 431\u2013439 (2023).","journal-title":"Ann. Oncol."},{"key":"1160_CR162","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio, M. et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J. Clin. Oncol. 33, 910\u2013915 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR163","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch, E. et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J. Natl Cancer Inst. 106, dju244 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"1160_CR164","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.161","volume":"36","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d\/c) due to treatment-related adverse events (TRAEs): results from CheckMate 9DW [abstract 148O]. Ann. Oncol. 36, S62\u2013S63 (2025).","journal-title":"Ann. Oncol."},{"key":"1160_CR165","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jnci\/djae223","volume":"117","author":"J Zhao","year":"2025","unstructured":"Zhao, J. et al. Allostatic load, genetic susceptibility, incidence risk, and all-cause mortality of colorectal cancer. J. Natl Cancer Inst. 117, 134\u2013143 (2025).","journal-title":"J. Natl Cancer Inst."},{"key":"1160_CR166","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/oncolo\/oyac109","volume":"27","author":"LR Roberts","year":"2022","unstructured":"Roberts, L. R. et al. Unmet needs in oncology clinical research and treatment in Africa: focus on Ghana. Oncologist 27, 760\u2013767 (2022).","journal-title":"Oncologist"},{"key":"1160_CR167","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"1160_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101350","volume":"7","author":"RS Finn","year":"2025","unstructured":"Finn, R. S. et al. Second-line pembrolizumab for advanced HCC: meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies. JHEP Rep. 7, 101350 (2025).","journal-title":"JHEP Rep."},{"key":"1160_CR169","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"1160_CR170","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(22)00270-4","volume":"23","author":"F Bray","year":"2022","unstructured":"Bray, F. et al. Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs. Lancet Oncol. 23, 719\u2013728 (2022).","journal-title":"Lancet Oncol."},{"key":"1160_CR171","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim, E. S. et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J. Clin. Oncol. 35, 3737\u20133744 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1160_CR172","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2025.04.028","volume":"83","author":"CAM Fulgenzi","year":"2025","unstructured":"Fulgenzi, C. A. M. et al. Hepatocellular carcinoma in people living with HIV. J. Hepatol. 83,\u00a0971\u2013981\u00a0(2025).","journal-title":"J. Hepatol."},{"key":"1160_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0324807","volume":"20","author":"K Sliwinski","year":"2025","unstructured":"Sliwinski, K., Miller, J. E. & Lynch, H. F. Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals. PLoS ONE 20, e0324807 (2025).","journal-title":"PLoS ONE"},{"key":"1160_CR174","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-23-1391","volume":"29","author":"LA Fashoyin-Aje","year":"2023","unstructured":"Fashoyin-Aje, L. A. et al. Driving diversity and inclusion in cancer drug development \u2014 industry and regulatory perspectives, current practices, opportunities, and challenges. Clin. Cancer Res. 29, 3566\u20133572 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1160_CR175","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jhep.2023.12.031","volume":"80","author":"LA Kondili","year":"2024","unstructured":"Kondili, L. A. et al. Inequities in primary liver cancer in Europe: the state of play. J. Hepatol. 80, 645\u2013660 (2024).","journal-title":"J. Hepatol."},{"key":"1160_CR176","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S1470-2045(24)00438-8","volume":"25","author":"LA Dawson","year":"2024","unstructured":"Dawson, L. A. et al. Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 25, 1337\u20131346 (2024).","journal-title":"Lancet Oncol."},{"key":"1160_CR177","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1007\/s12325-024-02939-1","volume":"41","author":"MA W\u00f6rns","year":"2024","unstructured":"W\u00f6rns, M. A. et al. Patient experience of hepatocellular carcinoma and their treatment goals: an international qualitative study and patient journey map. Adv. Ther. 41, 3598\u20133614 (2024).","journal-title":"Adv. Ther."},{"key":"1160_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101192","volume":"6","author":"JC Nault","year":"2024","unstructured":"Nault, J. C. et al. Patient and physician expectations regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study. JHEP Rep. 6, 101192 (2024).","journal-title":"JHEP Rep."},{"key":"1160_CR179","unstructured":"US Food and Drug Administration. Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-and-considerations-determining-whether-confirmatory-trial-underway (FDA, 2025)."},{"key":"1160_CR180","unstructured":"European Medicines Agency. Conditional Marketing Authorisation https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/conditional-marketing-authorisation?utm_source=chatgpt.com (EMA, 2026)."},{"key":"1160_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114022","volume":"202","author":"V Lesan","year":"2024","unstructured":"Lesan, V., Olivier, T. & Prasad, V. Progression-free survival estimates are shaped by specific censoring rules: implications for PFS as an endpoint in cancer randomized trials. Eur. J. Cancer 202, 114022 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1160_CR182","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2026","volume":"8","author":"A Tibau","year":"2025","unstructured":"Tibau, A. et al. Factors in time to full approval or withdrawal for anticancer medicines granted accelerated approval by the FDA. JAMA Netw. Open 8, e252026 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1160_CR183","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2040","volume":"8","author":"K Jenei","year":"2025","unstructured":"Jenei, K. & Booth, C. M. The delicate balancing act of accelerated approval for cancer medicines-speed, certainty, and benefit. JAMA Netw. Open 8, e252040 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1160_CR184","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S1470-2045(21)00709-9","volume":"23","author":"A Akhade","year":"2022","unstructured":"Akhade, A., Sirohi, B. & Gyawali, B. Global consequences of the US FDA\u2019s accelerated approval of cancer drugs. Lancet Oncol. 23, 201\u2013203 (2022).","journal-title":"Lancet Oncol."},{"key":"1160_CR185","unstructured":"European Medicines Agency. ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials Step 2b https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-2b-revision-1_en.pdf (EMA, 2017)."},{"key":"1160_CR186","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698\u2013711 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"1160_CR187","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/lt.24977","volume":"24","author":"JM Llovet","year":"2018","unstructured":"Llovet, J. M. et al. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl. 24, 369\u2013379 (2018).","journal-title":"Liver Transpl."},{"key":"1160_CR188","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402, 1133\u20131146 (2023).","journal-title":"Lancet"},{"key":"1160_CR189","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","volume":"26","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. Lancet Oncol. 26, 719\u2013731 (2025).","journal-title":"Lancet Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01160-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01160-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01160-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:01:06Z","timestamp":1784721666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01160-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":189,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01160-z","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"6 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.L. has acted as a consultant and\/or adviser for AstraZeneca, AbbVie, Bayer HealthCare Pharmaceuticals, B.I., BMS, Eisai, Genentech-Roche, Glycotest, Merck and Sanofi Aventis; and has received research support from Eisai and Genentech-Roche. E.M. has received travel funding from Roche. L.\u00a0Rimassa has acted as a consultant and\/or adviser for AbbVie, AstraZeneca, Basilea, Bayer, BMS, Boehringer Ingelheim, Eisai, Elevar Therapeutics, Exelixis, Genenta, Guerbet, Hengrui, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology and Zymeworks; has received lecture fees from AstraZeneca, Bayer, Biologix, BMS, Eisai, Guerbet, Incyte, Ipsen, Roche and Servier; travel funding from AstraZeneca and Servier; and research grants from AbbVie, AstraZeneca, BeiGene, Exelixis, Fibrogen, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences and Zymeworks. M.P. has acted as a consultant and\/or adviser for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Lilly, MSD and Roche; has received honoraria for acting as a speaker for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Lilly, MSD and Roche; has received research grants from AstraZeneca, Bayer, BMS, Eisai and Roche; and has received travel support from AstraZeneca, Bayer, BMS, Ipsen and Roche. R.K.K. has acted as a consultant and\/or adviser for Agios, AstraZeneca, BMS, Exelixis, Ipsen and Merck; has received fees for acting as a consultant and\/or adviser for Astra Zeneca, CVS Caremark, Genmab, GSK, Jazz, Moderna and Tallac; has received research funding from Agios, AstraZeneca, Bayer, BMS, the Cholangiocarcinoma Foundation, Compass Therapeutics, Eli Lilly, Exelixis, Genentech\/Roche, Merck, Novartis, Partner Therapeutics, QED, Relay Therapeutics, Servier, Taiho and Tyra Biosciences; and has received travel support from AstraZeneca and Merck. S.L.C. has acted as an adviser for AstraZeneca, BMS, Eisai, Hengrui, Ipsen and MSD; has received research funding from MSD, Eisai, Ipsen, SIRTEX and Zailab; and has received honoraria from AstraZeneca, Eisai, Roche, Ipsen and MSD. L.K. has acted as an adviser for AstraZeneca, Genetech\/Roche and TRACER. A.P. has acted as an adviser for AstraZeneca, Boston Scientific, Eisai, Exelixis, Fujifilm, Genentech and Sirtex. B.S. has acted as a consultant and\/or adviser for AstraZeneca, Bayer, BMS, Boston Scientific, Exelixis, Ipsen, MSD, Roche, Sirtex Medical and Terumo; has received research funding from BMS and Roche; and has acted as a speaker for AstraZeneca, Bayer, BMS, Roche, Sirtex Medical and Terumo. A.V. has acted as a consultant and\/or adviser for Abbvie, AstraZenca, Biologix, Boehringer Ingelheim, BMS, Cogent, EISAI, Elevar, Ipsen, Incyte, Jazzpharma, Medivir, MSD, Roche, Servier, Tahio, Terumo, Tyra and Zymeworks. M.Y. has received research funding from BMS, Exelixis, Genentech and Incyte; has received honoraria from AstraZeneca, Exelixis, Genentech, Incyte and Lantheus; is listed as a co-inventor on patents related to cancer vaccines; and is a cofounder with equity in Adventris Pharmaceuticals. R.S.F. has acted as an adviser for AstraZeneca, Bayer, BMS, Eisia, Genentech, Merck, Novartis, Pfizer, Roche and Zai Labs. T.M. has received research funding from Bayer, Boston Scientific and MSD; and has acted as a consultant for AstraZeneca, Geneos, Grey Wolf, Guerbet, Ipsen, Roche and Signant health. A.G.S. has acted as a consultant and\/or adviser for Abbott, AstraZeneca, Bayer, Boston Scientific, DELFI, Eisai, Elevar, Exact, Exelixis, FujiFilm Medical Sciences, Genentech, Glycotest, HelioGenomics, HistoSonics, IMCare, Merck, Roche, Sirtex and Universal Dx.\u00a0The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}